,
Moise Matakone,
Laurent Akono,
Charles Kouanfack,
Lucien Honoré Sone Etame
Background and Purpose: Candidiasis are the most frequent fungal infection, especially in immunocompromised people such as patients living with the human immunodeficiency virus (PLHIV). Data on the fungal prevalence and antifungal resistance rate particularly in PLHIV in Cameroon are scarce. This study aimed to determine the distribution and the antifungal resistance profile of Candida spp. isolated from clinical samples of PLHIV visiting the laboratory service of the Yaoundé Central Hospital. Materials and Methods: A cross-sectional study was carried out on the PLHIV visiting the Central Hospital of Yaoundé laboratory service. Samples were collected according to the signs and symptoms recorded by the patient and inoculated onto Sabouraud + Chloramphenicol agar medium for 24 hours incubation at 35°C ± 2°C. Typical Candida colonies were subjected to a germ tube test to identify Candida albicans and the other species were identified biochemically using API Candida (BioMérieux). The antifungal susceptibility testing was carried out by the disk diffusion method and seven antifungal discs (Bioanalyse) were tested. Results: Overall, 106 unique samples were obtained from participants. The positivity rate of Candida spp. was 37.7%. Candida isolates were mostly recovered from sputum (n=15/40) followed by the oral swabs (n=10/40) and the vaginal swabs (n=08/40). Out of the 40 isolates, Candida albicans was the predominant species 57.5% followed by Candida krusei 15%, Candida glabrata and Candida guilliermondii 10% each and Candida famata 7.5%. The antifungal drug resistance profile of Candida spp. revealed the highest resistance rates to Amphotericin B (95.0%), Fluconazole (57.5%) and Nystatin (42.5%). Conversely, Clotrimazole, Miconazole and Econazole were the most effective against Candida spp. Conclusion: The high frequency of Candida spp. isolation, resistant to several commonly used antifungals among PLHIV in a hospital setting is a direct call for stakeholders, policymakers and clinicians about antifungal therapy awareness in this vulnerable population.
| Published in | International Journal of Microbiology and Biotechnology (Volume 9, Issue 2) |
| DOI | 10.11648/j.ijmb.20240902.12 |
| Page(s) | 37-42 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
PLHIV, Candida, Antifungal Drug Resistance
3.1. Socio-Demographic Characteristics of Participants
Variables | Modality | Frequency (106) | Positive culture n (%) |
|---|---|---|---|
Age (years) | 20 -30 | 17 | 10 (58.8) |
31 – 40 | 27 | 12 (44.4) | |
41 -50 | 23 | 08 (34.7) | |
50+ | 39 | 11 (28.2) | |
Gender | Male | 66 | 18 (27.3) |
Female | 40 | 23 (57.5) | |
Matrimonial status | Single | 18 | 08 (44.4) |
Married | 72 | 30 (41.7) | |
Widow | 16 | 03 (18.8) | |
Educational level | Illiterate | 17 | 06 (35.3) |
Primary | 33 | 12 (36.4) | |
Secondary | 35 | 09 (25.7) | |
University | 21 | 14 (66.7) |
3.2. Distribution of Candida spp. Isolates
Candida spp. | Samples (%) | ||||
|---|---|---|---|---|---|
Sputum | Oral swab | Vaginal swabs | Stool | Urines | |
Candida albicans (23) | 08 (34.8) | 03 (13.0) | 05 (21.7) | 04 (17.4) | 03 (13.0) |
Candida famata (03) | 00 | 01 (33.3) | 02 (66.7) | 00 | 00 |
Candida glabrata (04) | 00 | 03 (75.0) | 01 (25.0) | 00 | 00 |
Candida guilliermondii (04) | 01 (25.0) | 03 (75.0) | 00 | 00 | 00 |
Candida krusei (06) | 06 (100.0) | 00 (0.0) | 00 (0.0) | 00 (0.0) | 00 |
Total (n=40) | 15 | 10 | 08 | 04 | 03 |
3.3. Antifungal Resistance Profile
Isolates (n) | Resistance rate n (%) | ||||||
|---|---|---|---|---|---|---|---|
ECO | CLT | FLU | MCZ | KTC | AMB | NY | |
Total (40) | 11 (27.5) | 10 (25.0) | 23 (57.5) | 11 (27.5) | 16 (40.0) | 38 (95.0) | 17 (42.5) |
Candida albicans (23) | 06 (26.1) | 06 (26.1) | 11 (47.8) | 03 (13.0) | 07 (30.4) | 22 (95.7) | 10 (42.5) |
Candida famata (03) | 00 | 01 (33.3) | 01 (33.3) | 00 | 01 (33.3) | 03 (100) | 01 (33.3) |
Candida glabrata (04) | 01 (25.0) | 02 (50.0) | 02 (50.0) | 01 (25.0) | 02 (50.0) | 03 (75.0) | 01 (25.0) |
Candida guilliermondii (04) | 01 (25) | 00 | 03 (75.0) | 03 (75.0) | 02 (50.0) | 04 (100) | 02 (50.0) |
Candida krusei (06) | 03 (50.0) | 01 (16.7) | 06 (100) | 04 (66.7) | 03 (50.0) | 06 (100) | 03 (50.0) |
| [1] |
Sanjay G. Revanker M. Candidose cutanéomuqueuse Wayne State University School of medecine 2021 Available from:
https://www.msdmanuals.com/fr/professional/maladies-infectieuses/mycoses/blastomycose |
| [2] |
OMS. L’OMS publie la toute première liste d’agents pathogènes fongiques 2022 Available from:
https://www.who.int/fr/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi |
| [3] | Anna N, Nsagha DS, Assob J, Kamga HL, Teyim P. Candidiasis in HIV and AIDS Patients Attending the Nylon Health District Hospital in Douala, Cameroon. TAF Preventive Medicine Bulletin. 2011; 10: 1. |
| [4] | Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care. 2011; 1: 37. |
| [5] | Cassone A, Cauda R. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. Aids. 2012; 26(12): 1457-72. |
| [6] | Bonnin A. The commensal-pathogen transition in invasive Candida albicans infection: molecular and cellular approaches. Bull Acad Natl Med. 2012; 196(1): 139-49. |
| [7] | Hani U, Shivakumar HG, Vaghela R, Osmani RA, Shrivastava A. Candidiasis: a fungal infection--current challenges and progress in prevention and treatment. Infect Disord Drug Targets. 2015; 15(1): 42-52. |
| [8] | Bekolo CE, Kouanfack C, Ateudjieu J, Bechem ET, Ndeso SA, Tendengfor N, et al. The declining trend in HIV prevalence from population-based surveys in Cameroon between 2004 and 2018: myth or reality in the universal test and treat era? BMC Public Health. 2023; 23(1): 479. |
| [9] | Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258): 1204-22. |
| [10] | MoPH. Health Sector Strategy 2016-2027. Yaounde 2016. |
| [11] | Ilham HAOUAR. Les infections urinaires à l’hôpital militaire d’instruction Mohammed V de Rabat: Fréquence, répartition et antibiorésistance des bactéries isolées dans les urines: UNIVERSITE MOHAMMED V; 2010. |
| [12] | Viñuela-Sandoval L, Falces-Romero I, García-Rodríguez J, Eiros-Bouza JM. Candidemia y colonización por Candida auris, un reto diagnóstico. Enfermedades Infecciosas y Microbiología Clínica. 2018; 36(4): 253-5. |
| [13] | Njunda AL, Nsagha DS, Assob JC, Kamga HL, Teyim P. In vitro Antifungal Susceptibility Patterns of Candida albicans from HIV and AIDS Patients Attending the Nylon Health District Hospital in Douala, Cameroon. J Public Health Afr. 2012; 3(1): e2. |
| [14] | Ambe NF, Longdoh NA, Tebid P, Bobga TP, Nkfusai CN, Ngwa SB, et al. The prevalence, risk factors and antifungal sensitivity pattern of oral candidiasis in HIV/AIDS patients in Kumba District Hospital, South West Region, Cameroon. Pan Afr Med J. 2020; 36: 23. |
| [15] | Clark-Ordóñez I, Callejas-Negrete OA, Aréchiga-Carvajal ET, Mouriño-Pérez RR. Candida species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico. Med Mycol. 2017; 55(3): 285-94. |
| [16] | Khedri S, Santos ALS, Roudbary M, Hadighi R, Falahati M, Farahyar S, et al. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species. Lett Appl Microbiol. 2018; 67(4): 392-9. |
| [17] | Gugnani HC, Denning DW, Rahim R, Sadat A, Belal M, Mahbub MS. Burden of serious fungal infections in Bangladesh. Eur J Clin Microbiol Infect Dis. 2017; 36(6): 993-7. |
| [18] | Dos Santos Abrantes PM, McArthur CP, Africa CW. Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon. Diagn Microbiol Infect Dis. 2014; 79(2): 222-7. |
| [19] | Lehman LG, Kangam L, Mbenoun ML, Zemo Nguepi E, Essomba N, Tonga C, et al. Intestinal parasitic and candida infection associated with HIV infection in Cameroon. J Infect Dev Ctries. 2013; 7(2): 137-43. |
| [20] | Njunda LA, Assob J, Nsagha SD, Kamga HL, Ndellejong EC, Kwenti TE. Oral and urinary colonization of Candida species in HIV/AIDS patients in Cameroon. Basic Sci Med. 2013; 2(1): 1-8. |
| [21] | Gonsu Kamga HY, Kechia Agem, F., Tegankam, D., Toukam, M., Sando, Z., & Moyou Somo, R,. Sensibilité aux Antifongiques des Candida Spp Isolés dans les Candidoses Digestives chez les Sujets Séropositifs au VIH à Yaoundé-Cameroun. HEALTH SCIENCES AND DISEASE. 2014; 15(3). |
APA Style
Kamdem, A. S., Gueguim, C., Matakone, M., Akono, L., Kouanfack, C., et al. (2024). Distribution and Antifungal Resistance Profile of Candida spp. Isolated from Patients Living with HIV at the Yaoundé Central Hospital. International Journal of Microbiology and Biotechnology, 9(2), 37-42. https://doi.org/10.11648/j.ijmb.20240902.12
ACS Style
Kamdem, A. S.; Gueguim, C.; Matakone, M.; Akono, L.; Kouanfack, C., et al. Distribution and Antifungal Resistance Profile of Candida spp. Isolated from Patients Living with HIV at the Yaoundé Central Hospital. Int. J. Microbiol. Biotechnol. 2024, 9(2), 37-42. doi: 10.11648/j.ijmb.20240902.12
AMA Style
Kamdem AS, Gueguim C, Matakone M, Akono L, Kouanfack C, et al. Distribution and Antifungal Resistance Profile of Candida spp. Isolated from Patients Living with HIV at the Yaoundé Central Hospital. Int J Microbiol Biotechnol. 2024;9(2):37-42. doi: 10.11648/j.ijmb.20240902.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijmb.20240902.12,
author = {Ashley Sonmele Kamdem and Cedric Gueguim and Moise Matakone and Laurent Akono and Charles Kouanfack and Lucien Honoré Sone Etame},
title = {Distribution and Antifungal Resistance Profile of Candida spp. Isolated from Patients Living with HIV at the Yaoundé Central Hospital
},
journal = {International Journal of Microbiology and Biotechnology},
volume = {9},
number = {2},
pages = {37-42},
doi = {10.11648/j.ijmb.20240902.12},
url = {https://doi.org/10.11648/j.ijmb.20240902.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijmb.20240902.12},
abstract = {Background and Purpose: Candidiasis are the most frequent fungal infection, especially in immunocompromised people such as patients living with the human immunodeficiency virus (PLHIV). Data on the fungal prevalence and antifungal resistance rate particularly in PLHIV in Cameroon are scarce. This study aimed to determine the distribution and the antifungal resistance profile of Candida spp. isolated from clinical samples of PLHIV visiting the laboratory service of the Yaoundé Central Hospital. Materials and Methods: A cross-sectional study was carried out on the PLHIV visiting the Central Hospital of Yaoundé laboratory service. Samples were collected according to the signs and symptoms recorded by the patient and inoculated onto Sabouraud + Chloramphenicol agar medium for 24 hours incubation at 35°C ± 2°C. Typical Candida colonies were subjected to a germ tube test to identify Candida albicans and the other species were identified biochemically using API Candida (BioMérieux). The antifungal susceptibility testing was carried out by the disk diffusion method and seven antifungal discs (Bioanalyse) were tested. Results: Overall, 106 unique samples were obtained from participants. The positivity rate of Candida spp. was 37.7%. Candida isolates were mostly recovered from sputum (n=15/40) followed by the oral swabs (n=10/40) and the vaginal swabs (n=08/40). Out of the 40 isolates, Candida albicans was the predominant species 57.5% followed by Candida krusei 15%, Candida glabrata and Candida guilliermondii 10% each and Candida famata 7.5%. The antifungal drug resistance profile of Candida spp. revealed the highest resistance rates to Amphotericin B (95.0%), Fluconazole (57.5%) and Nystatin (42.5%). Conversely, Clotrimazole, Miconazole and Econazole were the most effective against Candida spp. Conclusion: The high frequency of Candida spp. isolation, resistant to several commonly used antifungals among PLHIV in a hospital setting is a direct call for stakeholders, policymakers and clinicians about antifungal therapy awareness in this vulnerable population.},
year = {2024}
}
TY - JOUR T1 - Distribution and Antifungal Resistance Profile of Candida spp. Isolated from Patients Living with HIV at the Yaoundé Central Hospital AU - Ashley Sonmele Kamdem AU - Cedric Gueguim AU - Moise Matakone AU - Laurent Akono AU - Charles Kouanfack AU - Lucien Honoré Sone Etame Y1 - 2024/04/17 PY - 2024 N1 - https://doi.org/10.11648/j.ijmb.20240902.12 DO - 10.11648/j.ijmb.20240902.12 T2 - International Journal of Microbiology and Biotechnology JF - International Journal of Microbiology and Biotechnology JO - International Journal of Microbiology and Biotechnology SP - 37 EP - 42 PB - Science Publishing Group SN - 2578-9686 UR - https://doi.org/10.11648/j.ijmb.20240902.12 AB - Background and Purpose: Candidiasis are the most frequent fungal infection, especially in immunocompromised people such as patients living with the human immunodeficiency virus (PLHIV). Data on the fungal prevalence and antifungal resistance rate particularly in PLHIV in Cameroon are scarce. This study aimed to determine the distribution and the antifungal resistance profile of Candida spp. isolated from clinical samples of PLHIV visiting the laboratory service of the Yaoundé Central Hospital. Materials and Methods: A cross-sectional study was carried out on the PLHIV visiting the Central Hospital of Yaoundé laboratory service. Samples were collected according to the signs and symptoms recorded by the patient and inoculated onto Sabouraud + Chloramphenicol agar medium for 24 hours incubation at 35°C ± 2°C. Typical Candida colonies were subjected to a germ tube test to identify Candida albicans and the other species were identified biochemically using API Candida (BioMérieux). The antifungal susceptibility testing was carried out by the disk diffusion method and seven antifungal discs (Bioanalyse) were tested. Results: Overall, 106 unique samples were obtained from participants. The positivity rate of Candida spp. was 37.7%. Candida isolates were mostly recovered from sputum (n=15/40) followed by the oral swabs (n=10/40) and the vaginal swabs (n=08/40). Out of the 40 isolates, Candida albicans was the predominant species 57.5% followed by Candida krusei 15%, Candida glabrata and Candida guilliermondii 10% each and Candida famata 7.5%. The antifungal drug resistance profile of Candida spp. revealed the highest resistance rates to Amphotericin B (95.0%), Fluconazole (57.5%) and Nystatin (42.5%). Conversely, Clotrimazole, Miconazole and Econazole were the most effective against Candida spp. Conclusion: The high frequency of Candida spp. isolation, resistant to several commonly used antifungals among PLHIV in a hospital setting is a direct call for stakeholders, policymakers and clinicians about antifungal therapy awareness in this vulnerable population. VL - 9 IS - 2 ER -
Higher Institute of Medical Technology, Yaoundé, Cameroon
Higher Institute of Medical Technology, Yaoundé, Cameroon; Department of Environmental Sciences, Higher Institute of Agriculture, Wood, Water and the Environment, University of Bertoua, Bertoua, Cameroon
Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon
Higher Institute of Medical Technology, Yaoundé, Cameroon
Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon
Higher Institute of Medical Technology, Yaoundé, Cameroon; Institute for Medical Research and Medicinal Plant Studies, Yaoundé, Cameroon
Information